Cargando…
Toxicity in combined therapies for tumours treatments: a lesson from BAG3 in the TME?
Autores principales: | Rosati, Alessandra, Marzullo, Liberato, De Marco, Margot, De Laurenzi, Vincenzo, D’Amico, Maria Francesca, Turco, Maria Caterina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406442/ https://www.ncbi.nlm.nih.gov/pubmed/37554328 http://dx.doi.org/10.3389/fimmu.2023.1241543 |
Ejemplares similares
-
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration
por: Dufrusine, Beatrice, et al.
Publicado: (2021) -
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer
por: Iorio, Vittoria, et al.
Publicado: (2018) -
Development of an anti‐BAG3 humanized antibody for treatment of pancreatic cancer
por: Basile, Anna, et al.
Publicado: (2019) -
Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’
por: De Marco, Margot, et al.
Publicado: (2020) -
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth
por: De Marco, Margot, et al.
Publicado: (2022)